Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions

Background HIV‐1 replication can be inhibited with RNA interference (RNAi) by expression of short hairpin RNA (shRNA) from a lentiviral vector. Because lentiviral vectors are based on HIV‐1, viral sequences in the vector system are potential targets for the antiviral shRNAs. Here, we investigated al...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of gene medicine 2007-09, Vol.9 (9), p.743-750
Hauptverfasser: ter Brake, Olivier, Berkhout, Ben
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 750
container_issue 9
container_start_page 743
container_title The journal of gene medicine
container_volume 9
creator ter Brake, Olivier
Berkhout, Ben
description Background HIV‐1 replication can be inhibited with RNA interference (RNAi) by expression of short hairpin RNA (shRNA) from a lentiviral vector. Because lentiviral vectors are based on HIV‐1, viral sequences in the vector system are potential targets for the antiviral shRNAs. Here, we investigated all possible routes by which shRNAs can target the lentiviral vector system. Methods Expression cassettes for validated shRNAs with targets within HIV‐1 Leader, Gag‐Pol, Tat/Rev and Nef sequences were inserted in the lentiviral vector genome. Third‐generation self‐inactivating HIV‐1‐based lentiviral vectors were produced and lentiviral vector capsid production and transduction titer determined. Results RNAi against HIV‐1 sequences within the vector backbone results in a reduced transduction titer while capsid production was unaffected. The notable exception is self‐targeting of the shRNA encoding sequence, which does not affect transduction titer. This is due to folding of the stable shRNA hairpin structure, which masks the target for the RNAi machinery. Targeting of Gag‐Pol mRNA reduces both capsid production and transduction titer, which was improved with a human codon‐optimized Gag‐Pol construct. When Rev mRNA was targeted, no reduction in capsid production and transduction titer was observed. Conclusions Lentiviral vector titers can be negatively affected when shRNAs against the vector backbone and the Gag‐Pol mRNA are expressed during lentiviral vector production. Titer reductions due to targeting of the Gag‐Pol mRNA can be avoided with a human codon‐optimized Gag‐Pol packaging plasmid. The remaining targets in the vector backbone may be modified by point mutations to resist RNAi‐mediated degradation during vector production. Copyright © 2007 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/jgm.1078
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68202404</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19739128</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4158-451dd1e5db794ec57055542577421e36b9d9569f84181c0e347d63af42dd833</originalsourceid><addsrcrecordid>eNqF0F1LwzAUBuAgis4p-AukeCHeVJM0aRLvVHSbTgUnU7wJaZO5zn5o0k73742sKAjiVQ6ch5eTF4AdBA8RhPho9lz4gfEV0EEUoxBjSlb9DIUIieCPG2DTuRmEiHEu1sEGYjHmEIsOOB-ass7mmVV5MDdpXVkX1FNVB6mydhEovwz7g3Hgpnc3J-44eLVVkpvC-Y0OXJU3dVaVbgusTVTuzHb7dsHo4vz-rB8Ob3uDs5NhmBJEeUgo0hoZqhMmiEkpg5RSgiljBCMTxYnQgsZiwgniKIUmIkzHkZoQrDWPoi7YX6b6I94a42pZZC41ea5KUzVOxhxDTCD5FyLBIoEw93DvF5xVjS39F7yJueAxpx4dLFFqK-esmchXmxXKLiSC8qt-6euXX_V7utvmNUlh9A9s-_YgXIL3LDeLP4PkZe-6DWx95mrz8e2VfZExixiVDzc9eS2unkZ3p2OJo09QX5se</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196898685</pqid></control><display><type>article</type><title>Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions</title><source>MEDLINE</source><source>Wiley Online Library</source><creator>ter Brake, Olivier ; Berkhout, Ben</creator><creatorcontrib>ter Brake, Olivier ; Berkhout, Ben</creatorcontrib><description>Background HIV‐1 replication can be inhibited with RNA interference (RNAi) by expression of short hairpin RNA (shRNA) from a lentiviral vector. Because lentiviral vectors are based on HIV‐1, viral sequences in the vector system are potential targets for the antiviral shRNAs. Here, we investigated all possible routes by which shRNAs can target the lentiviral vector system. Methods Expression cassettes for validated shRNAs with targets within HIV‐1 Leader, Gag‐Pol, Tat/Rev and Nef sequences were inserted in the lentiviral vector genome. Third‐generation self‐inactivating HIV‐1‐based lentiviral vectors were produced and lentiviral vector capsid production and transduction titer determined. Results RNAi against HIV‐1 sequences within the vector backbone results in a reduced transduction titer while capsid production was unaffected. The notable exception is self‐targeting of the shRNA encoding sequence, which does not affect transduction titer. This is due to folding of the stable shRNA hairpin structure, which masks the target for the RNAi machinery. Targeting of Gag‐Pol mRNA reduces both capsid production and transduction titer, which was improved with a human codon‐optimized Gag‐Pol construct. When Rev mRNA was targeted, no reduction in capsid production and transduction titer was observed. Conclusions Lentiviral vector titers can be negatively affected when shRNAs against the vector backbone and the Gag‐Pol mRNA are expressed during lentiviral vector production. Titer reductions due to targeting of the Gag‐Pol mRNA can be avoided with a human codon‐optimized Gag‐Pol packaging plasmid. The remaining targets in the vector backbone may be modified by point mutations to resist RNAi‐mediated degradation during vector production. Copyright © 2007 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 1099-498X</identifier><identifier>EISSN: 1521-2254</identifier><identifier>DOI: 10.1002/jgm.1078</identifier><identifier>PMID: 17628029</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Capsid - metabolism ; Cell Line ; Codon - genetics ; Fusion Proteins, gag-pol - metabolism ; Gene Products, rev - metabolism ; Gene therapy ; Genes, Reporter ; Genetic Vectors ; Genome, Viral - genetics ; HIV - drug effects ; HIV-1 ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Humans ; lentiviral vector ; Lentivirus - drug effects ; Lentivirus - genetics ; Mutation - genetics ; RNA, Small Interfering - pharmacology ; RNA, Viral ; RNAi ; shRNA ; shRNA, gene therapy ; Transduction, Genetic</subject><ispartof>The journal of gene medicine, 2007-09, Vol.9 (9), p.743-750</ispartof><rights>Copyright © 2007 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4158-451dd1e5db794ec57055542577421e36b9d9569f84181c0e347d63af42dd833</citedby><cites>FETCH-LOGICAL-c4158-451dd1e5db794ec57055542577421e36b9d9569f84181c0e347d63af42dd833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjgm.1078$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjgm.1078$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17628029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ter Brake, Olivier</creatorcontrib><creatorcontrib>Berkhout, Ben</creatorcontrib><title>Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions</title><title>The journal of gene medicine</title><addtitle>J. Gene Med</addtitle><description>Background HIV‐1 replication can be inhibited with RNA interference (RNAi) by expression of short hairpin RNA (shRNA) from a lentiviral vector. Because lentiviral vectors are based on HIV‐1, viral sequences in the vector system are potential targets for the antiviral shRNAs. Here, we investigated all possible routes by which shRNAs can target the lentiviral vector system. Methods Expression cassettes for validated shRNAs with targets within HIV‐1 Leader, Gag‐Pol, Tat/Rev and Nef sequences were inserted in the lentiviral vector genome. Third‐generation self‐inactivating HIV‐1‐based lentiviral vectors were produced and lentiviral vector capsid production and transduction titer determined. Results RNAi against HIV‐1 sequences within the vector backbone results in a reduced transduction titer while capsid production was unaffected. The notable exception is self‐targeting of the shRNA encoding sequence, which does not affect transduction titer. This is due to folding of the stable shRNA hairpin structure, which masks the target for the RNAi machinery. Targeting of Gag‐Pol mRNA reduces both capsid production and transduction titer, which was improved with a human codon‐optimized Gag‐Pol construct. When Rev mRNA was targeted, no reduction in capsid production and transduction titer was observed. Conclusions Lentiviral vector titers can be negatively affected when shRNAs against the vector backbone and the Gag‐Pol mRNA are expressed during lentiviral vector production. Titer reductions due to targeting of the Gag‐Pol mRNA can be avoided with a human codon‐optimized Gag‐Pol packaging plasmid. The remaining targets in the vector backbone may be modified by point mutations to resist RNAi‐mediated degradation during vector production. Copyright © 2007 John Wiley &amp; Sons, Ltd.</description><subject>Capsid - metabolism</subject><subject>Cell Line</subject><subject>Codon - genetics</subject><subject>Fusion Proteins, gag-pol - metabolism</subject><subject>Gene Products, rev - metabolism</subject><subject>Gene therapy</subject><subject>Genes, Reporter</subject><subject>Genetic Vectors</subject><subject>Genome, Viral - genetics</subject><subject>HIV - drug effects</subject><subject>HIV-1</subject><subject>Human immunodeficiency virus</subject><subject>Human immunodeficiency virus 1</subject><subject>Humans</subject><subject>lentiviral vector</subject><subject>Lentivirus - drug effects</subject><subject>Lentivirus - genetics</subject><subject>Mutation - genetics</subject><subject>RNA, Small Interfering - pharmacology</subject><subject>RNA, Viral</subject><subject>RNAi</subject><subject>shRNA</subject><subject>shRNA, gene therapy</subject><subject>Transduction, Genetic</subject><issn>1099-498X</issn><issn>1521-2254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0F1LwzAUBuAgis4p-AukeCHeVJM0aRLvVHSbTgUnU7wJaZO5zn5o0k73742sKAjiVQ6ch5eTF4AdBA8RhPho9lz4gfEV0EEUoxBjSlb9DIUIieCPG2DTuRmEiHEu1sEGYjHmEIsOOB-ass7mmVV5MDdpXVkX1FNVB6mydhEovwz7g3Hgpnc3J-44eLVVkpvC-Y0OXJU3dVaVbgusTVTuzHb7dsHo4vz-rB8Ob3uDs5NhmBJEeUgo0hoZqhMmiEkpg5RSgiljBCMTxYnQgsZiwgniKIUmIkzHkZoQrDWPoi7YX6b6I94a42pZZC41ea5KUzVOxhxDTCD5FyLBIoEw93DvF5xVjS39F7yJueAxpx4dLFFqK-esmchXmxXKLiSC8qt-6euXX_V7utvmNUlh9A9s-_YgXIL3LDeLP4PkZe-6DWx95mrz8e2VfZExixiVDzc9eS2unkZ3p2OJo09QX5se</recordid><startdate>200709</startdate><enddate>200709</enddate><creator>ter Brake, Olivier</creator><creator>Berkhout, Ben</creator><general>John Wiley &amp; Sons, Ltd</general><general>Wiley Periodicals Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7QO</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200709</creationdate><title>Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions</title><author>ter Brake, Olivier ; Berkhout, Ben</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4158-451dd1e5db794ec57055542577421e36b9d9569f84181c0e347d63af42dd833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Capsid - metabolism</topic><topic>Cell Line</topic><topic>Codon - genetics</topic><topic>Fusion Proteins, gag-pol - metabolism</topic><topic>Gene Products, rev - metabolism</topic><topic>Gene therapy</topic><topic>Genes, Reporter</topic><topic>Genetic Vectors</topic><topic>Genome, Viral - genetics</topic><topic>HIV - drug effects</topic><topic>HIV-1</topic><topic>Human immunodeficiency virus</topic><topic>Human immunodeficiency virus 1</topic><topic>Humans</topic><topic>lentiviral vector</topic><topic>Lentivirus - drug effects</topic><topic>Lentivirus - genetics</topic><topic>Mutation - genetics</topic><topic>RNA, Small Interfering - pharmacology</topic><topic>RNA, Viral</topic><topic>RNAi</topic><topic>shRNA</topic><topic>shRNA, gene therapy</topic><topic>Transduction, Genetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ter Brake, Olivier</creatorcontrib><creatorcontrib>Berkhout, Ben</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>Biotechnology Research Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The journal of gene medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ter Brake, Olivier</au><au>Berkhout, Ben</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions</atitle><jtitle>The journal of gene medicine</jtitle><addtitle>J. Gene Med</addtitle><date>2007-09</date><risdate>2007</risdate><volume>9</volume><issue>9</issue><spage>743</spage><epage>750</epage><pages>743-750</pages><issn>1099-498X</issn><eissn>1521-2254</eissn><abstract>Background HIV‐1 replication can be inhibited with RNA interference (RNAi) by expression of short hairpin RNA (shRNA) from a lentiviral vector. Because lentiviral vectors are based on HIV‐1, viral sequences in the vector system are potential targets for the antiviral shRNAs. Here, we investigated all possible routes by which shRNAs can target the lentiviral vector system. Methods Expression cassettes for validated shRNAs with targets within HIV‐1 Leader, Gag‐Pol, Tat/Rev and Nef sequences were inserted in the lentiviral vector genome. Third‐generation self‐inactivating HIV‐1‐based lentiviral vectors were produced and lentiviral vector capsid production and transduction titer determined. Results RNAi against HIV‐1 sequences within the vector backbone results in a reduced transduction titer while capsid production was unaffected. The notable exception is self‐targeting of the shRNA encoding sequence, which does not affect transduction titer. This is due to folding of the stable shRNA hairpin structure, which masks the target for the RNAi machinery. Targeting of Gag‐Pol mRNA reduces both capsid production and transduction titer, which was improved with a human codon‐optimized Gag‐Pol construct. When Rev mRNA was targeted, no reduction in capsid production and transduction titer was observed. Conclusions Lentiviral vector titers can be negatively affected when shRNAs against the vector backbone and the Gag‐Pol mRNA are expressed during lentiviral vector production. Titer reductions due to targeting of the Gag‐Pol mRNA can be avoided with a human codon‐optimized Gag‐Pol packaging plasmid. The remaining targets in the vector backbone may be modified by point mutations to resist RNAi‐mediated degradation during vector production. Copyright © 2007 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>17628029</pmid><doi>10.1002/jgm.1078</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1099-498X
ispartof The journal of gene medicine, 2007-09, Vol.9 (9), p.743-750
issn 1099-498X
1521-2254
language eng
recordid cdi_proquest_miscellaneous_68202404
source MEDLINE; Wiley Online Library
subjects Capsid - metabolism
Cell Line
Codon - genetics
Fusion Proteins, gag-pol - metabolism
Gene Products, rev - metabolism
Gene therapy
Genes, Reporter
Genetic Vectors
Genome, Viral - genetics
HIV - drug effects
HIV-1
Human immunodeficiency virus
Human immunodeficiency virus 1
Humans
lentiviral vector
Lentivirus - drug effects
Lentivirus - genetics
Mutation - genetics
RNA, Small Interfering - pharmacology
RNA, Viral
RNAi
shRNA
shRNA, gene therapy
Transduction, Genetic
title Lentiviral vectors that carry anti-HIV shRNAs: problems and solutions
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T15%3A51%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lentiviral%20vectors%20that%20carry%20anti-HIV%20shRNAs:%20problems%20and%20solutions&rft.jtitle=The%20journal%20of%20gene%20medicine&rft.au=ter%20Brake,%20Olivier&rft.date=2007-09&rft.volume=9&rft.issue=9&rft.spage=743&rft.epage=750&rft.pages=743-750&rft.issn=1099-498X&rft.eissn=1521-2254&rft_id=info:doi/10.1002/jgm.1078&rft_dat=%3Cproquest_cross%3E19739128%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196898685&rft_id=info:pmid/17628029&rfr_iscdi=true